Biological Evaluation

Biological Evaluation for Medical Devices

Our Biological Evaluation Services help ensure that medical devices meet essential safety and biocompatibility requirements before reaching the market. By combining scientific expertise with regulatory knowledge, we support manufacturers throughout the biological evaluation process, helping demonstrate device safety, performance, and compliance with applicable regulations.
Our experienced team provides Biological Evaluation Consulting tailored to the intended use, materials, and patient contact characteristics of each device, supporting both regulatory approval and long-term Medical Device Compliance.

The Importance of Biological Safety Assessment

Biological safety is a vital aspect of the medical device certification process. It evaluates the compatibility of materials used within a device to confirm they do not result in harmful biological responses and that safety and performance requirements under MDR 2017/745 are met.
A robust Biological Safety Assessment is essential for demonstrating Medical Device Biocompatibility, supporting regulatory certification, and safeguarding patient wellbeing throughout the product lifecycle.

What We Do? Comprehensive Biological Evaluation & Toxicological Risk Assessment Support

MDRA provides specialised support across the entire biological evaluation process, from Biological Evaluation Plan (BEP) development and material characterisation through to Toxicological Risk Assessment (TRA), Biological Evaluation Report (BER) preparation, and notified body submission support.

Our services are aligned with EU MDR 2017/745 requirements and ISO 10993 guidance to support scientifically justified, risk-based biological evaluations.

Our Biological Evaluation Services include:

• Biological Evaluation Plan (BEP) development.
• Material characterisation and data review.
• ISO 10993 Assessment support.
• Toxicological Risk Assessment (TRA).
• Biological Safety Assessment.
• Medical Device Biocompatibility evaluations.
• Biocompatibility Assessment planning and justification.
• Biological Evaluation Report (BER) preparation.
• Notified body submission support.
• Ongoing regulatory and lifecycle support.

Biological Evaluation Plan (BEP)

The Biological Evaluation Plan establishes the framework for evaluating biological risks associated with a medical device.
We develop a comprehensive Biological Evaluation Plan tailored to the device materials, intended use, patient contact characteristics, and regulatory requirements.

The plan typically includes:

• Identification of device materials.
• Assessment of biological hazards.
• Selection of required biocompatibility testing.
• Testing strategy and timelines.
• Biological risk management considerations.

Toxicological Risk Assessment (TRA)

A Toxicological Risk Assessment evaluates chemical constituents that may be released from a device and assesses their potential impact on patient safety.

Using material characterisation data, our team performs a structured Toxicology Risk Assessment based on:

• Intended patient population.
• Nature and duration of exposure.
• Potential toxicological hazards.
• Exposure thresholds and safety margins.
This risk-based approach helps determine whether additional testing is required and supports regulatory decision-making.

Risk Assessment

We conduct detailed evaluations of identified biological hazards associated with device materials and manufacturing processes.
Our engineers and regulatory specialists work collaboratively to identify risks, evaluate potential harm, and establish appropriate control measures.

This process includes:

• Hazard identification.
• Evaluation of potential patient harm.
• Risk control measures.
• Risk assessment documentation.
• Benefit-risk considerations.

Biological Evaluation Report (BER)

The Biological Evaluation Report is a key regulatory document used to demonstrate device biocompatibility and biological safety.
Our team develops a comprehensive Biological Evaluation Report aligned with MDR 2017/745 requirements and ISO 10993 principles.

Each report is designed to:

• Follow a science-based, risk-driven methodology.
• Document identified biological risks and mitigation measures.
• Support Medical Device Biocompatibility conclusions.
• Justify the selection or omission of testing.
• Demonstrate device safety for its intended purpose.

Regulatory Compliance

Biological evaluation is not simply a testing exercise. It is a scientific, risk-based assessment that considers how a medical device interacts with the human body throughout its lifecycle.
A structured ISO 10993 Assessment helps demonstrate that a device is safe for its intended use while supporting regulatory submissions and ongoing Medical Device Compliance.
Our Biological Evaluation Consulting services help manufacturers navigate evolving regulatory expectations while maintaining robust documentation and defensible scientific conclusions.

Regulatory & Lifecycle Support

Biological evaluation is an ongoing process that should evolve alongside product changes, regulatory updates, and post-market information.

MDRA provides ongoing support including:

• Regulatory review support aligned with notified body expectations.
• Responses to notified body questions.
• Biological Evaluation Report updates.
• Periodic review activities.
• Post-market surveillance support.
• Continued Biological Safety Assessment activities.

How We Work

Our Proven 5-Step biological evaluation Workflow

We deliver efficient, EU MDR-compliant Biological Evaluation Plans, Toxicological Risk Assessments, and Biological Evaluation Reports through a structured process designed to support regulatory review readiness.

1

Material Characterisation and Risk Assessment

Before testing begins, we evaluate:

• Device materials, coatings, and adhesives.
• Manufacturing and sterilisation processes.
• Duration and nature of patient contact.
• Existing safety and performance data.

This stage helps determine whether available evidence can support safety conclusions and reduce unnecessary testing.

2

Determination of Biological Risks Based on ISO 10993-1

ISO 10993-1 provides the framework used to determine relevant biological endpoints based on:

• Nature of body contact.
• Duration of contact.
• Device classification and intended use.

This forms the foundation of the overall Biocompatibility Assessment strategy.

3

Data Appraisal & Benefit-Risk Analysis

We evaluate available evidence and perform a structured Clinical and Biological Safety Assessment to determine whether additional testing is required and whether identified risks are acceptable.

4

Biocompatibility Testing (if required)

Where evidence gaps exist, testing may be required to support safety conclusions.
Examples include:

• Cytotoxicity testing.
• Sensitisation testing.
• Irritation testing.
• Systemic toxicity testing.

Where sufficient evidence exists through material characterisation and Toxicological Risk Assessment activities, certain tests may be reduced or avoided.

5

Justification of Biocompatibility for Regulatory Submission

The final Biological Evaluation Report documents:

• Material characterisation findings.
• Risk assessment conclusions.
• Testing outcomes where applicable.
• Scientific justification for omitted testing.
• Biological safety conclusions.

This documentation forms an important part of the technical file submitted for regulatory review.

Why Choose MDRA for Biological Evaluation:

MDRA provides strategic Biological Evaluation Services for medical device manufacturers seeking clear, compliant, and scientifically robust documentation.

Dedicated Biological Evaluation Experts

Our team includes experienced regulatory specialists, scientists, and engineers who support Biological Evaluation Plan development, Toxicological Risk Assessment activities, and Biological Evaluation Report authoring.

Integrated Technical Documentation Support

We align biological evaluation activities with clinical evaluation, risk management, and broader technical documentation requirements to support a consistent regulatory strategy.

Predictable, High-Quality Execution

By evaluating materials and biological risks early in the design and development process, we help manufacturers develop efficient and defensible biological evaluation strategies.

Turning Biological Evaluation into Regulatory Documentation

We transform complex biological and chemical data into clear regulatory narratives that support Medical Device Compliance, product safety demonstrations, and informed regulatory review.

Need Support with Biological Evaluation?

Whether you require a Biological Evaluation Plan, Biological Evaluation Report, ISO 10993 Assessment, Toxicological Risk Assessment, or broader Biological Evaluation Consulting support, MDRA can help.
Our team supports manufacturers across Canada, Australia, the UK, UAE, Europe, and other international markets with practical biological evaluation and biocompatibility expertise.

Biological Evaluation